Özlem Olguner Eker1, Saliha Özsoy2, Baki Eker3, Hatice Doğan4. 1. Department of Psychiatry, Kayseri Training and Research Hospital, Kayseri, Turkey. 2. Department of Psychiatry, Erciyes University School of Medicine, Kayseri, Turkey. 3. Department of Internal Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey. 4. Department of Child and Adolescent Psychiatry, Kayseri Training and Research Hospital, Kayseri, Turkey.
Abstract
INTRODUCTION: This study aimed to investigate body measurements, glucose-insulin metabolism, and lipid profile in patients with anxiety and depressive symptoms and also the effects of antidepressant drugs on these metabolic parameters. METHODS: The study included 40 outpatients and 32 healthy controls. The patients received antidepressant treatment (sertraline, escitalopram, fluoxetine, and venlafaxine) for 8 weeks. Body measurements were performed, and lipid, fasting blood glucose, and insulin levels were measured before and after treatment in patients and once in healthy controls. Insulin resistance was evaluated using the homeostasis model assessment (HOMA) index. RESULTS: Body mass index was higher in patients than in healthy controls, and there was no change in patients after treatment. In patients, high-density lipoprotein (HDL) cholesterol levels increased owing to the antidepressant treatment. Insulin level and HOMA index had a tendency to decrease with the treatment in patients and were similar to those of healthy controls before the treatment; however, they became lower than those of healthy controls after the treatment. There was an increase in waist circumference and total and HDL cholesterol levels, whereas there was a decrease in fasting blood glucose levels with treatment in patients using escitalopram. There was no change in body measurements and biochemical and hormone values in patients using fluoxetine, sertraline, and venlafaxine. There was an increase in weight, body mass index, and waist circumference after treatment in patients with depression; however, there was no change in patients with anxiety. CONCLUSION: In patients with psychiatric disorders having anxiety and depressive symptoms, metabolic changes independent of drugs and the metabolic effects of drugs are present.
INTRODUCTION: This study aimed to investigate body measurements, glucose-insulin metabolism, and lipid profile in patients with anxiety and depressive symptoms and also the effects of antidepressant drugs on these metabolic parameters. METHODS: The study included 40 outpatients and 32 healthy controls. The patients received antidepressant treatment (sertraline, escitalopram, fluoxetine, and venlafaxine) for 8 weeks. Body measurements were performed, and lipid, fasting blood glucose, and insulin levels were measured before and after treatment in patients and once in healthy controls. Insulin resistance was evaluated using the homeostasis model assessment (HOMA) index. RESULTS: Body mass index was higher in patients than in healthy controls, and there was no change in patients after treatment. In patients, high-density lipoprotein (HDL) cholesterol levels increased owing to the antidepressant treatment. Insulin level and HOMA index had a tendency to decrease with the treatment in patients and were similar to those of healthy controls before the treatment; however, they became lower than those of healthy controls after the treatment. There was an increase in waist circumference and total and HDL cholesterol levels, whereas there was a decrease in fasting blood glucose levels with treatment in patients using escitalopram. There was no change in body measurements and biochemical and hormone values in patients using fluoxetine, sertraline, and venlafaxine. There was an increase in weight, body mass index, and waist circumference after treatment in patients with depression; however, there was no change in patients with anxiety. CONCLUSION: In patients with psychiatric disorders having anxiety and depressive symptoms, metabolic changes independent of drugs and the metabolic effects of drugs are present.
Authors: Debbie A Lawlor; Yoav Ben-Shlomo; Shah Ebrahim; George Davey Smith; Stephen A Stansfeld; John W G Yarnell; John E J Gallacher Journal: BMJ Date: 2005-01-31
Authors: James A Dunbar; Prasuna Reddy; Nathalie Davis-Lameloise; Benjamin Philpot; Tiina Laatikainen; Annamari Kilkkinen; Stephen J Bunker; James D Best; Erkki Vartiainen; Sing Kai Lo; Edward D Janus Journal: Diabetes Care Date: 2008-10-03 Impact factor: 19.112
Authors: Panos Zanos; Cristan A Farmer; Ruin Moaddel; Bashkim Kadriu; Patrick J Morris; Jacqueline Lovett; Elia E Acevedo-Diaz; Grace W Cavanaugh; Peixiong Yuan; Mani Yavi; Craig J Thomas; Lawrence T Park; Luigi Ferrucci; Todd D Gould; Carlos A Zarate Journal: Transl Psychiatry Date: 2022-05-02 Impact factor: 7.989